Anika's Strategic Move: Sale of Arthrosurface Business

Deal News | Nov 07, 2024 | Goodwin

Anika Therapeutics, Inc., a leading global joint preservation company, has divested its Arthrosurface business in line with a strategic review to focus on high-potential orthopedic sectors such as Osteoarthritis Pain Management, Regenerative Solutions, and Sports Medicine. The company received a consideration of $10 million, which includes a non-interest-bearing promissory note for $7 million and up to $3 million additional consideration, contingent on the sales performance of Arthrosurface. The global operations of Anika are headquartered in Massachusetts, USA, and Goodwin's Life Sciences team advised on the transaction.

Sectors

  • Healthcare
  • Medical Devices
  • Legal Services

Geography

  • United States – Anika Therapeutics' global operations are headquartered just outside of Boston, Massachusetts.

Industry

  • Healthcare – Anika Therapeutics operates within the healthcare sector, focusing on joint preservation and orthopedic care.
  • Medical Devices – The sale of the Arthrosurface business, involved in orthopedic solutions, falls within the medical devices industry.
  • Legal Services – Goodwin provided legal advisory services, an essential role in the transaction.

Financials

  • $10 million – Total consideration for the sale of Arthrosurface, including a $7 million promissory note and up to $3 million based on performance.

Participants

NameRoleTypeDescription
Anika Therapeutics, Inc.TargetCompanyA global joint preservation company focused on orthopedic care.
ArthrosurfaceDivested businessCompanyA business unit sold by Anika, involved in orthopedic solutions.
GoodwinLegal AdvisorCompanyProvided legal advisory services for the transaction.